AAHFN Advanced 2020 - CCM® in HF - Mechanism and Clinical Evidence

February 3, 2021

This video is a lecture from AAHFN 2020 Product Theatre Session titled CCM® in Heart Failure: Mechanisms and Clinical Evidence. Dr. Rami Kahwash gives an overview of the clinical science behind CCM® therapy and the indications for patients that could benefit from this therapy.  Dr. Kahwash also touches upon the need to classify NYHA Heart Failure Classification when assessing a heart failure patient and how that can benefit the collaboration of care.  Finally, he reviews that any healthcare provider that can prescribe guideline directed medical therapy can also screen patients for CCM® therapy.

  • October 26, 2021 - U.S. Food and Drug Administration approved a modification of labeling for the Optimizer® Smart medical device, allowing the removal of “normal sinus rhythm” (NSR) from the indications for use statement as of 10/26/2021. Please note that this presentation was done prior to this FDA update.
Login to view comments. Click here to Login